GLP-1 receptor agonist (acylated GLP-1 analogue)
Liraglutide — evidence
What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.
Evidence overview
No evidence records in this file yet.
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Regulatory notes
FDA-approved drug substance
- VICTOZA, NDA 022341, approved 25 January 2010. SAXENDA, NDA 206321, approved 23 December 2014. Both are listed as prescription products in Drugs@FDA.
- Drugs@FDA lists abbreviated new drug applications for generic liraglutide, the earliest dated 23 December 2024.
- FDA proposed in April 2026 to exclude liraglutide, semaglutide and tirzepatide from the 503B bulks list.
- Not named on the WADA 2026 Prohibited List.
Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.
No records in this file match the current filter. That is an empty result, not a finding about the compound.
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built